期刊文献+

HIV疫苗临床试验研究进展 被引量:4

Research progress of HIV vaccine clinical trials
原文传递
导出
摘要 近年来虽然艾滋病防治取得了巨大进展,HIV疫苗依然是人类彻底战胜艾滋病的重要"武器"。HIV疫苗的研发历程坎坷,多种技术路线的疫苗进入临床试验阶段,但尚未获得成功。本文通过查阅US Clinical Trials数据库(clinicaltrials.gov)和中国药物临床试验登记与信息公示平台数据库,根据疫苗的技术路线,包括传统疫苗、重组亚单位蛋白疫苗、重组病毒载体类疫苗、核酸疫苗,总结了近十年进入临床试验阶段的HIV疫苗,重点阐述了进入临床Ⅲ期的疫苗和最有潜力的疫苗。 In recent years, although great progress has been made in the prevention and treatment of AIDS, the HIV vaccine is still an important "weapon" for mankind to completely defeat AIDS. However, the development of the HIV vaccine is bumpy, and several HIV vaccines with multiple technical routes have entered the stage of human clinical trials,but have not yet been successful. This article summarizes the HIV vaccines that have entered human clinical trials in the past ten years by searching the US Clinical Trials database(ClinicalTrials. gov) and the Platform for drug clinical trial registration and information publicity in China, including traditional vaccines, recombinant subunit protein vaccines,recombinant viral vector vaccines, nucleic acid vaccines, focusing on the most promising HIV vaccines and vaccines in the phase Ⅲ stage.
作者 聂玲玲 黄维金 NIE Lingling;HUANG Weijin(National Institutes for Food and Drug Control,Key Laboratory of National Health Commission of the People's Republic of China for Research on Quality and Standardization of Biotech Products,Key Laboratory of Biological Product Quality Research and Evaluation of State Drug Administration,Beijing 102629,China)
出处 《中国艾滋病性病》 CAS CSCD 北大核心 2022年第2期220-227,共8页 Chinese Journal of Aids & STD
基金 国家“十三五”重大专项课题资助项目(2018ZX10731101-002-006)。
关键词 艾滋病病毒 疫苗 临床试验 AIDS vaccine clinical trails
  • 相关文献

参考文献1

二级参考文献28

  • 1林长乐,曾耀英,曾祥凤,赵令斋,王通,李海仙,李莉平.鹰嘴豆芽素A抗HIV-1活性及抑制CD4^+淋巴细胞早期活化作用[J].中国药理学通报,2007,23(2):214-218. 被引量:12
  • 2Davis M R, Jiang J, Zhou J, et al. A mutation in the human immunodeficiency virus type 1 Gag protein destabilizes the interaction of the envelope protein subunits gp120 and gp41 [J]. J Virol, 2006, 80(5): 2405-17.
  • 3Sen J, Jacobs A, Caffrey M. Role of the HIV gp120 conserved domain 5 in processing and viral entry[ J]. Biochemistry, 2008, 47 (30) :7788 -95.
  • 4Kim S, Pang H B, Kay M S. Peptide mimic of the HIV envelope gp120-gp41 interface [ J ]. J Mol Biol, 2008, 376 ( 3 ) :786 - 97.
  • 5Kaushik-Bausu N, Basu A, Harris D. Peptide inhibition of HIV-1 : current status and future potential [ J ]. BioDrugs, 2008, 22 ( 3 ) : 161 -75.
  • 6Crublet E, Andrieu J P, Vives R R, et al. The HIV-I envelope glycoprotein gpl20 features four heparan sulfate binding domains, including the co-receptor binding site [ J ]. J Biol Chem, 2008,283(22):15193 -200.
  • 7Kwong P D, Wyatt R, Robinson J, et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody [ J ], Nature, 1998, 393 (6686) : 648 - 59.
  • 8Chen B, Vogan E M, Gong H, et al. Structure of an unliganded simian immunodeficicncy virus gpl20 core[J]. Nature, 2005, 433 (7028) :834 -41.
  • 9Liu J, Bartesaghi A, Borgnia M J, et al. Molecular architecture of native HIV-1 gpl20 trimers[J]. Nature, 2008, 455(7209) :109 -13.
  • 10McFadden K, Cocklin S, Gopi H, et al. A recombinant allosteric lectin antagonist of HIV-1 envelope gp120 interactions [ J]. Proteins, 2007, 67(3):617-29.

共引文献6

同被引文献32

引证文献4

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部